ATRX-Deficient High-Grade Glioma Cells Exhibit Increased Sensitivity to RTK and PDGFR Inhibitors
Simple Summary
- Supplementary File 1:
ZIP-Document (ZIP, 2772 KiB)
Pladevall-Morera, D.; Castejón-Griñán, M.; Aguilera, P.; Gaardahl, K.; Ingham, A.; Brosnan-Cashman, J.A.; Meeker, A.K.; Lopez-Contreras, A.J. ATRX-Deficient High-Grade Glioma Cells Exhibit Increased Sensitivity to RTK and PDGFR Inhibitors. Cancers 2022, 14, 1790. https://doi.org/10.3390/cancers14071790
Pladevall-Morera D, Castejón-Griñán M, Aguilera P, Gaardahl K, Ingham A, Brosnan-Cashman JA, Meeker AK, Lopez-Contreras AJ. ATRX-Deficient High-Grade Glioma Cells Exhibit Increased Sensitivity to RTK and PDGFR Inhibitors. Cancers. 2022; 14(7):1790. https://doi.org/10.3390/cancers14071790
Chicago/Turabian StylePladevall-Morera, David, María Castejón-Griñán, Paula Aguilera, Karina Gaardahl, Andreas Ingham, Jacqueline A. Brosnan-Cashman, Alan K. Meeker, and Andres J. Lopez-Contreras. 2022. "ATRX-Deficient High-Grade Glioma Cells Exhibit Increased Sensitivity to RTK and PDGFR Inhibitors" Cancers 14, no. 7: 1790. https://doi.org/10.3390/cancers14071790